These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 28506066)

  • 21. A vascular endothelial growth factor 121 (VEGF(121))-based dual PET/optical probe for in vivo imaging of VEGF receptor expression.
    Kang CM; Koo HJ; Lee KC; Choe YS; Choi JY; Lee KH; Kim BT
    Biomaterials; 2013 Sep; 34(28):6839-45. PubMed ID: 23787114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
    Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
    Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
    Huhtala T; Laakkonen P; Sallinen H; Ylä-Herttuala S; Närvänen A
    Nucl Med Biol; 2010 Nov; 37(8):957-64. PubMed ID: 21055627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
    Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
    Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
    Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
    Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and
    Okarvi SM; Aljammaz I
    Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
    Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
    J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
    Shamay Y; Golan M; Tyomkin D; David A
    J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P; Knight LC; Welch MJ
    Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
    J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
    Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
    Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
    Laverman P; Béhé M; Oyen WJ; Willems PH; Corstens FH; Behr TM; Boerman OC
    Bioconjug Chem; 2004; 15(3):561-8. PubMed ID: 15149184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
    Gao H; Zhang Q; Yang Y; Jiang X; He Q
    Int J Pharm; 2015 Jan; 478(1):240-250. PubMed ID: 25448586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
    Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
    Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas.
    Kumar SR; Quinn TP; Deutscher SL
    Clin Cancer Res; 2007 Oct; 13(20):6070-9. PubMed ID: 17947470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.